阿托伐他汀联合rhBNP在AMI合并心力衰竭中的疗效及对心肾功能、PⅢNP和hs-CRP水平的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (603 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Atorvastatin combined with recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute myocardial infarction (AMI) with heart failure (HF), and its effects on cardiorenal function and levels of procollagen Ⅲ N-terminal peptide (PⅢNP) and high sensitive C reactive protein (hs-CRP). Methods Ninety cases of patients with AMI and HF in Xinjiang General Hospital of Armed Police Forces from October 2015 to October 2016 were divided into control group (45 cases) and treatment group (45 cases) by random number table method. On the basis of routine treatment, control group was treated by Atorvastatin Calcium Tablets, treatment group was treated by Atorvastatin Calcium Tablets and rhBNP. The cardiorenal function, levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), PⅢNP and hs-CRP as well as major adverse cardiovascular events (MACE) and adverse reactions before and after treatment were compared. Results Before treatment, there were no statistically significant differences of left ventricular ejection fractions (LVEF), left ventricular end systolic volume (LVESV) and left ventricular end diastolic volume (LVEDV) between the two groups (P > 0.05). After treatment, the levels of LVEF in the two groups were significantly higher than those before treatment (P ＜ 0.05), while the levels of LVESV and LVEDV were significantly lower than those before treatment (P ＜ 0.05), and the variation range of the treatment group was greater than that of the control group (P ＜ 0.05). Before treatment, there were no significant differences in the levels of creatinine (Cr), cystatin-C (Cys-C), blood urea nitrogen (BUN) and uric acid (UA) between the two groups (P > 0.05). After treatment, the levels of Cr and Cys-C in treatment group were significantly lower than those before treatment (P ＜ 0.05) , while there were no signfiicant differences of the levels of BUN and UA in the two groups compared with those before treatment (P ＞ 0.05). And the levels of Cr, Cys-C, BUN and UA also showed no significant differences between the two groups after treatment (P ＞ 0.05). Before treatment, there were no significant differences of NT-proBNP, PⅢNP and hs-CRP between the two groups (P > 0.05). After treatment, the levels of NT-proBNP, PⅢNP and hs-CRP in the two groups were significantly lower than those before treatment (P ＜ 0.05), and the variation range of the treatment group was greater than that of the control group (P ＜ 0.05). The risk of MACE and all-cause death in the treatment group were significantly lower than those of the control group (P ＜ 0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Atorvastatin combined with rhBNP in treatment of patients with AMI and HF can significantly improve the cardiorenal function of the patients, effectively regulate the levels of PⅢNP and hs-CRP, and significantly reduce the risk of MACE and death of the patients.

Key words： Myocardial infarction Heart failure Atorvastatin Cardiorenal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Adilijiang·Tuohuti1 Alimujiang·Abulaiti2 LI Jie1 LI Guoqing1

Cite this article:

Adilijiang·Tuohuti1 Alimujiang·Abulaiti2 LI Jie1 LI Guoqing1. Clinical efficacy of Atorvastatin combined with rhBNP in AMI patients with heart failure and its effects on cardiorenal function and levels of PⅢNP and hs-CRP[J]. 中国医药导报, 2018, 15(26): 38-42.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I26/38

[1] Meng Khoo C，Tai ES. Trends in the incidence and mortality of coronary heart disease in asian pacific region：the Singapore experience [J]. J Atheroscler Thromb，2014（21 Suppl 1）：S2-S8.
[2] Dalen JE，Alpert JS，Goldberg RJ，et al. The epidemic of the 20（th）century：coronary heart disease [J]. Am J Med，2014，127（9）：807-812.
[3] 刘晓娟，王岚峰.首发急性心肌梗死患者入院期间心力衰竭的相关因素[J].心血管病学进展，2017，38（6）：687-691.
[4] Kudo S，Satoh K，Nogi M，et al. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis：Novel Mechanism of the Pleiotropic Effects of Statins [J]. Hypertension，2016，67（5）：878-889.
[5] 曾晓铧，王静，谭洁.重组人脑钠肽治疗急性心力衰竭的研究进展[J].医学综述，2015，21（1）：61-63.
[6] 高润霖.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001，29（12）：710-725.
[7] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[8] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43（5）：380-393.
[9] Lee TF，Burt MG，Heilbronn LK，et al. Relative hyperglycemia is associated with complications following an acute myocardial infarction：a post-hoc analysis of HI-5 data [J]. Cardiovasc Diabetol，2017，16（1）：157.
[10] Radosavljevic-Radovanovic M，Radovanovic N，Vasiljevic Z，et al. Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction [J]. J Med Biochem，2016，35（2）：158-165.
[11] Sangaralingham SJ，Burnett JC，McKie PM，et al. Rationale and design of a randomized，double-blind，placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction [J]. J Card Fail，2013，19（8）：533-539.
[12] 张洪，徐革.急性肾小球肾炎早期肾损伤评估中Cys C、BUN、sCr检测的意义[J].海南医学院学报，2016，22（5）：447-449.
[13] Reichert K，Pereira do Carmo HR，Galluce Torina A，et al. Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism [J]. PLoS One，2016，11（11）：e0166845.
[14] Niu JM，Ma ZL，Xie C，et al. Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction [J]. Genet Mol Res，2014，13（3）：6177-6183.
[15] Durak-Nalbanti■ A，D?觩ubur A，Dili■ M，et al. Brain natriuretic peptide release in acute myocardial infarction [J]. Bosn J Basic Med Sci，2012，12（3）：164-168.
[16] Stumpf C，Sheriff A，Zimmermann S，et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty [J]. Arch Med Sci，2017， 13（5）：1086-1093.
[17] Choi SY，Park JS，Roh MS，et al. Inhibition of Angiotensin Ⅱ-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice [J]. Lipids，2017，52（5）：415-422.
[18] Jin F. Analysis on mechanism of ATP-sensitive K+ channel opener natakalim improving congestive heart failure after myocardial infarction [J]. Exp Ther Med，2016，12（6）：3993-3997.
[19] Wang Y，Gu X，Fan W，et al. Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction [J]. Am J Transl Res，2016，8（1）：239-245.
[20] 孙阿林，张光芳，肖丽，等.冻干重组人脑利钠肽对兔心肌梗死后心肌组织病理改变的影响及机制[J].山东医药，2016，56（20）：31-33.